The Concept of CMR
Slides, videos and moreEvaluating CMR
Metabolic Syndrome and Type 2 Diabetes/CVD Risk
Limitations
- 1Key Points (1 page)
- 2An Ongoing Debate (2 pages)
- 3Differences Between Existing Guidelines (2 pages)
- 4The Metabolic Syndrome is a Progressive Disorder (2 pages)
- 5Is the Whole Greater Than the Sum of its Parts? (1 page)
- 6Conclusion (1 page)
- 7References (1 page)
The Metabolic Syndrome is a Progressive Disorder
7 of 10
This suggests that the presence of even a few metabolic traits might reflect ongoing abnormalities that increase CVD risk and need to be treated aggressively.
To address this issue, Macchia et al. (10) sought to generate a diagnostic score to predict late-onset diabetes in the metabolic syndrome by assigning the appropriate weight to individual components of the metabolic syndrome. Data came from the GISSI-Prevenzione Study that included 11,323 patients with prior myocardial infarction followed for 3.5 years. This global assessment risk score assigned each component of the metabolic syndrome a proportion based on its association with diabetes (β coefficients). The metabolic syndrome score was found to have stronger ties to incident diabetes than NCEP-ATP III criteria, with an area under the receiver operating characteristic curve of 0.650 and 0.587 for the score and NCEP-ATP III criteria, respectively. Accordingly, this global approach to diagnosing the metabolic syndrome may be a better predictor of diabetes than any other current screening tool. However, this diagnostic score remains to be tested for CVD endpoints.
7 of 10
